BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Consensus Rating of "Moderate Buy" by Analysts

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twenty-three brokerages that are currently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $93.45.

Several analysts have recently issued reports on BMRN shares. Wedbush reissued an "outperform" rating and set a $94.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Citigroup reduced their price objective on BioMarin Pharmaceutical from $82.00 to $78.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. StockNews.com raised BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Piper Sandler lifted their price objective on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a research note on Thursday, February 20th. Finally, Bank of America raised their target price on shares of BioMarin Pharmaceutical from $99.00 to $103.00 and gave the company a "buy" rating in a research note on Thursday, February 20th.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, CAO Erin Burkhart sold 1,786 shares of the business's stock in a transaction dated Tuesday, May 20th. The shares were sold at an average price of $59.31, for a total value of $105,927.66. Following the completion of the sale, the chief accounting officer now owns 14,173 shares of the company's stock, valued at approximately $840,600.63. The trade was a 11.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 4,698 shares of company stock valued at $308,172 in the last three months. Corporate insiders own 0.85% of the company's stock.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Institutional investors have recently made changes to their positions in the company. Norges Bank bought a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at about $234,645,000. Nuveen LLC acquired a new position in shares of BioMarin Pharmaceutical in the 1st quarter valued at $184,475,000. Capital Research Global Investors boosted its position in shares of BioMarin Pharmaceutical by 23.8% in the 4th quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company's stock valued at $853,944,000 after purchasing an additional 2,496,817 shares during the period. AQR Capital Management LLC lifted its position in shares of BioMarin Pharmaceutical by 127.9% in the 1st quarter. AQR Capital Management LLC now owns 2,925,805 shares of the biotechnology company's stock valued at $203,987,000 after acquiring an additional 1,642,206 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in BioMarin Pharmaceutical by 212.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,592,963 shares of the biotechnology company's stock valued at $112,607,000 after buying an additional 1,083,512 shares during the period. 98.71% of the stock is currently owned by institutional investors.

BioMarin Pharmaceutical Trading Up 0.9%

NASDAQ:BMRN traded up $0.52 during trading hours on Monday, reaching $59.93. 2,964,184 shares of the company were exchanged, compared to its average volume of 1,871,220. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.33 and a quick ratio of 2.62. The firm has a market cap of $11.49 billion, a price-to-earnings ratio of 27.24, a PEG ratio of 0.61 and a beta of 0.27. BioMarin Pharmaceutical has a 52-week low of $52.93 and a 52-week high of $94.85. The stock has a 50 day simple moving average of $63.41 and a 200 day simple moving average of $64.99.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The biotechnology company reported $0.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 9.91%. The company had revenue of $747.31 million during the quarter, compared to analysts' expectations of $711.05 million. As a group, analysts predict that BioMarin Pharmaceutical will post 3.15 EPS for the current year.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.